In pancreatic tumors, HAT1 has shown its ability for influencing tumor proliferation and immunity, as well as treatment resistance, supporting its potential role as a relevant diagnostic, prognostic and predictive marker for cancer therapy [26,27]. This evidence concerns the gene HAT1 and pancreatic neoplasm.